SCHEMBL6154103

SCHEMBL6154103

CC(C)Oc1cc(NC2CCN(Cc3ccccc3)CC2)ccc1C(N)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.51
LTA4H P09960 1/20 0.48
CCR5 P51681 2/20 0.48
JAK2 O60674 1/20 0.48
JAK1 P23458 1/20 0.48
TYK2 P29597 1/20 0.48
JAK3 P52333 1/20 0.48
SIGMAR1 Q99720 2/20 0.48
ACHE P22303 2/20 0.46
OPRK1 P41145 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
ADRA2A P08913 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
DRD2 P14416 1/20 0.46
ADRA2B P18089 1/20 0.46
ADRA2C P18825 1/20 0.46
DRD4 P21917 1/20 0.46
SLC6A2 P23975 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6153691 0.89 MCHR1 (0.60) MCHR1SIGMAR1ACHEOPRK1CYP1A2
SCHEMBL6154946 0.87 LTA4H (0.52) MCHR1LTA4HCCR5JAK2JAK1
SCHEMBL6154970 0.85 MCHR1 (0.56) MCHR1SIGMAR1ACHEOPRK1CYP1A2
SCHEMBL6155471 0.85 LTA4H (0.50) MCHR1LTA4HJAK2JAK1TYK2
SCHEMBL6153705 0.84 LTA4H (0.48) MCHR1LTA4HJAK2JAK1TYK2
SCHEMBL6154132 0.83 POLB (0.56) MCHR1LTA4HJAK2JAK1TYK2
SCHEMBL6154543 0.82 SLC6A12 (0.59) LTA4HJAK2JAK1TYK2JAK3
SCHEMBL6155299 0.82 JAK2 (0.53) LTA4HJAK2JAK1TYK2JAK3
SCHEMBL6153444 0.81 SIGMAR1 (0.55) MCHR1LTA4HJAK2JAK1TYK2
SCHEMBL6153708 0.81 JAK2 (0.52) LTA4HJAK2JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 MCHR1 1952/4885LTA4H 1043/4885CCR5 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.